A drug developed by National Taiwan University Hospital (NTUH) has been approved for sale in the European Union for the treatment of aromatic-L-amino acid decarboxylase (AADC) deficiency, a rare life-threatening disorder that affects children, the hospital said Friday.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Business
Nokia's acquisition of Infinera approved by FTC
02/13/2025 03:43 PM - Society
4 dead, 20 injured in Taichung mall blast (update 2)
02/13/2025 03:10 PM - Society
Taiwan headline news
02/13/2025 02:56 PM - Business
Taiwan shares close up 0.47%
02/13/2025 01:57 PM - Society
One dead, 10 injured in explosion at Taichung department store (update 1)
02/13/2025 01:17 PM